Discover Booster Therapeutics' novel 20S proteasome activation approach to neurodegenerative diseases as it launches with $15 ...

Find out more about five biomimicry companies harnessing nature’s wisdom to create drug candidates for the benefit of human ...

Biotech IPO activity in the US has spiked for the second time this year, following an initial boost in Q1 2024. Largely ...

Take a closer look at 12 biotech unicorns, with a worth of more than $1 billion, that are trying to revolutionize the ...

Explore innovative treatments for spinal cord injury in clinical trials, including Lineage's OPC1 and NervGen's NVG-291, ...

Learn how cancer tissue biobanks and insights into solid tumor heterogeneity are transforming drug discovery and leading to ...

Discover six innovative clinical-stage biotech companies fostering R&D in the Duchenne muscular dystrophy therapeutic space.

Discover the major biotech partnerships, collaborations and mergers and acquisitions that made headlines in September 2024.

Find out all about the first two FDA drug approvals for the rare genetic disorder Niemann-Pick disease type C.

Find out about Resolution Therapeutics' macrophage therapy, as it just raised $85 million in a series B round.

The companies Candid Therapeutics, ArsenalBio, and eGenesis bagged the biggest private biotech investments in September 2024.